Yes / Appeals have been made for eye care professionals to start prescribing anti-myopia therapies as part of their routine management of myopic children. 1–3 These calls are fuelled by two key considerations. Firstly, that interventions to slow myopia progression have shown success in randomized controlled trials (RCTs) 4–7, and secondly, appreciation that the risk of sight-threatening complications rises dose-dependently with the level of myopia. 8,9 Notwithstanding existing gaps in knowledge regarding the efficacy of current treatments (see below), these considerations argue that myopia control interventions should be widely adopted, and that they should be instigated at an early age – especially in children most at risk – in order to reduce the final level of myopia. Therefore in managing a child with myopia, an eye care professional would have to decide not only which therapy to recommend, but at what age to start treatment. In this review we discuss the future role of genetic prediction in helping clinicians treat myopia. / NIHR Senior Research Fellowship. Grant Number: SRF‐2015‐08‐005
| Identifer | oai:union.ndltd.org:BRADFORD/oai:bradscholars.brad.ac.uk:10454/17506 |
| Date | 08 November 2019 |
| Creators | Guggenheim, J.A., Ghorbani Mojarrad, Neema, Williams, C., Flitcroft, D.I. |
| Source Sets | Bradford Scholars |
| Language | English |
| Detected Language | English |
| Type | Article, Accepted manuscript |
| Rights | © 2017 The Authors Ophthalmic & Physiological Optics © 2017 The College of Optometrists. This is the peer reviewed version of the following article: Guggenheim JA, Ghorbani Mojarrad N, Williams C et al (2017) Genetic prediction of myopia: prospects and challenges. Ophthalmic & Physiological Optics. 37(5): 549-556, which has been published in final form at https://doi.org/10.1111/opo.12403. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
Page generated in 0.0172 seconds